Article Text

other Versions

PDF
Where are we with RSV prophylaxis?
  1. Neil A Caldwell1,
  2. Ceri Townsend2
  1. 1Department of Pharmacy, Wirral University Teaching Hospital NHS Foundation Trust, Wirral, UK
  2. 2Department of Paediatrics, Wirral University Teaching Hospital, Wirral, UK
  1. Correspondence to Neil A Caldwell, Department of Pharmacy, Wirral University Teaching Hospital NHS Foundation Trust, Arrowe Park Hospital, Arrowe Park Road, Upton, Wirral CH495PE, UK; neil.caldwell{at}nhs.net

Abstract

Respiratory syncytial virus (RSV) is a predictable, seasonal disease with significant morbidity and mortality in children below 24 months. Prophylaxis, which decreases hospitalisation in those most vulnerable to the disease, has been available since 1998. Pharmacological prophylaxis is however, expensive and requires good infrastructure to deliver. It is out of reach for many patients in low-income and middle-income countries where mortality is highest. This article looks at the pathophysiology and risk factors for RSV. It also outlines what agents are currently available for prophylaxis and prevention.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Epistle
    Ian Wacogne
  • Guideline review
    Emma Caffrey Osvald Jane R Clarke